Contractor Information

Noridian Healthcare Solutions, LLC A and B MAC 01111 - MAC A J - E California - Entire State
Noridian Healthcare Solutions, LLC A and B MAC 01112 - MAC B J - E California - Northern
Noridian Healthcare Solutions, LLC A and B MAC 01182 - MAC B J - E California - Southern
Noridian Healthcare Solutions, LLC A and B MAC 01211 - MAC A J - E American Samoa
Noridian Healthcare Solutions, LLC A and B MAC 01212 - MAC B J - E Guam
Noridian Healthcare Solutions, LLC A and B MAC 01311 - MAC A J - E Northern Mariana Islands
Noridian Healthcare Solutions, LLC A and B MAC 01312 - MAC B J - E Guam
Noridian Healthcare Solutions, LLC A and B MAC 01911 - MAC A J - E Hawaii
Noridian Healthcare Solutions, LLC A and B MAC 01912 - MAC B J - E American Samoa
Noridian Healthcare Solutions, LLC A and B MAC 01913 - MAC B J - E Guam
Noridian Healthcare Solutions, LLC A and B MAC 01914 - MAC B J - E Hawaii
Noridian Healthcare Solutions, LLC A and B MAC 01915 - MAC B J - E Northern Mariana Islands

Article Information

General Information

Article ID
A55094

Article Title
MolDX: ApoE Genotype Billing and Coding Guidelines

AMA CPT / ADA CDT / AHA NUBC Copyright Statement
CPT only copyright 2002-2016 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Original Article Effective Date
10/10/2016

Revision Effective Date
N/A

Revision Ending Date
N/A

Retirement Date
N/A
The MolDX Team has determined Apolipoprotein (Apo) E genotype testing, developed to assess the risk of cardiovascular disease, has insufficient evidence to support the required clinical utility for the established Medicare benefit category. Therefore, ApoE Genotype tests are statutorily excluded tests.

As reviewed, the developers described the indication to perform an Apolipoprotein (Apo) E genotype test as a risk assessment for developing a disease or condition. Risk assessment for developing a disease or condition in the absence of signs and symptoms of an illness or injury is also not defined as a Medicare benefit. Therefore, Apolipoprotein (Apo) E genotype tests would continue to be statutory excluded tests.

To receive an ApoE service denial, please submit the following claim information:

- CPT code 81401- APOE, common variant
- An Advance Beneficiary Notice (ABN) is not required for statutorily excluded services
  - For a voluntary issued ABN, append with GX modifier
  - To indicate a statutorily excluded service, append with a GY modifier
- Select the appropriate diagnosis for the patient
- Enter the appropriate Identifier adjacent to each code used to report the service in the comment/narrative field for the following claim field/types:
  - Loop 2400 or SV101-7 for the 5010A1 837P
  - Box 19 for paper claim

Reference: Sec. 1862 (1)(A) Statutory Exclusion covers diagnostic testing “except for items and services that are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member,…”

Coding Information

Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the article should be assumed to apply equally to all claims.

N/A
Revenue Codes:

 Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the article should be assumed to apply equally to all Revenue Codes.

N/A

CPT/HCPCS Codes

Group 1 Paragraph: N/A

<table>
<thead>
<tr>
<th>Group 1 CPT/HCPCS Code</th>
<th>Group 1 CPT/HCPCS Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81401</td>
<td>MOLECULAR PATHOLOGY PROCEDURE, LEVEL 2 (EG, 2-10 SNPS, 1 METHYLATED VARIANT, OR 1 SOMATIC VARIANT [TYPICALLY USING NONSEQUENCING TARGET VARIANT ANALYSIS], OR DETECTION OF A DYNAMIC MUTATION DISORDER/TRIPLET REPEAT)</td>
</tr>
</tbody>
</table>

ICD-10 Codes that are Covered N/A
ICD-10 Codes that are Not Covered N/A

Revision History Information

N/A Related Local Coverage Document(s) N/A
Related National Coverage Document(s) N/A
Statutory Requirements URL(s) N/A
Rules and Regulations URL(s) N/A
CMS Manual Explanations URL(s) N/A
Other URL(s) N/A
Public Version(s) Updated on 08/10/2016 with effective dates 10/10/2016 - N/A

Keywords

- MoIDX
- ApoE
- Apolipoprotein
- 81401

Read the Article Disclaimer Back to Top